An update on the management of irritable bowel syndrome

J. P. Reilly, Colin Howden

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Irritable bowel syndrome (IBS) is a common, chronic disorder producing disturbances in defecation, abdominal pain, and bloating. While IBS is not considered a life-threatening disease, patients afflicted with it experience a decrease in quality of life. IBS is associated with significant disability, high health care costs, and decreased productivity at work. There is no single pathophysiologic marker for IBS. Application of diagnostic criteria and limited laboratory and clinical testing usually allow for a conclusive diagnosis. Understanding the pathophysiology and psychosocial factors in IBS can better prepare health care providers to improve patient outcomes. Treatment is based on an effective physician-patient relationship in conjunction with pharmacotherapy and behavioral modifications. The advent of new pharmacologic therapies acting at the 5-hyroxytryptamine receptor pathways will enable prescribers to better control IBS symptoms and improve quality of life.

Original languageEnglish (US)
Pages (from-to)11-16
Number of pages6
JournalDrug Benefit Trends
Volume12
Issue numberSUPPL. B
StatePublished - Jan 1 2000

Fingerprint

Irritable Bowel Syndrome
Quality of Life
Physician-Patient Relations
Defecation
Health Personnel
Health Care Costs
Abdominal Pain
Psychology
Drug Therapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Health Policy
  • Pharmacology (medical)

Cite this

An update on the management of irritable bowel syndrome. / Reilly, J. P.; Howden, Colin.

In: Drug Benefit Trends, Vol. 12, No. SUPPL. B, 01.01.2000, p. 11-16.

Research output: Contribution to journalReview article

Reilly, J. P. ; Howden, Colin. / An update on the management of irritable bowel syndrome. In: Drug Benefit Trends. 2000 ; Vol. 12, No. SUPPL. B. pp. 11-16.
@article{8a5e1eb84404441bb30a380f71d63bfb,
title = "An update on the management of irritable bowel syndrome",
abstract = "Irritable bowel syndrome (IBS) is a common, chronic disorder producing disturbances in defecation, abdominal pain, and bloating. While IBS is not considered a life-threatening disease, patients afflicted with it experience a decrease in quality of life. IBS is associated with significant disability, high health care costs, and decreased productivity at work. There is no single pathophysiologic marker for IBS. Application of diagnostic criteria and limited laboratory and clinical testing usually allow for a conclusive diagnosis. Understanding the pathophysiology and psychosocial factors in IBS can better prepare health care providers to improve patient outcomes. Treatment is based on an effective physician-patient relationship in conjunction with pharmacotherapy and behavioral modifications. The advent of new pharmacologic therapies acting at the 5-hyroxytryptamine receptor pathways will enable prescribers to better control IBS symptoms and improve quality of life.",
author = "Reilly, {J. P.} and Colin Howden",
year = "2000",
month = "1",
day = "1",
language = "English (US)",
volume = "12",
pages = "11--16",
journal = "Drug Benefit Trends",
issn = "1080-5826",
publisher = "Cliggott Publishing Co.",
number = "SUPPL. B",

}

TY - JOUR

T1 - An update on the management of irritable bowel syndrome

AU - Reilly, J. P.

AU - Howden, Colin

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Irritable bowel syndrome (IBS) is a common, chronic disorder producing disturbances in defecation, abdominal pain, and bloating. While IBS is not considered a life-threatening disease, patients afflicted with it experience a decrease in quality of life. IBS is associated with significant disability, high health care costs, and decreased productivity at work. There is no single pathophysiologic marker for IBS. Application of diagnostic criteria and limited laboratory and clinical testing usually allow for a conclusive diagnosis. Understanding the pathophysiology and psychosocial factors in IBS can better prepare health care providers to improve patient outcomes. Treatment is based on an effective physician-patient relationship in conjunction with pharmacotherapy and behavioral modifications. The advent of new pharmacologic therapies acting at the 5-hyroxytryptamine receptor pathways will enable prescribers to better control IBS symptoms and improve quality of life.

AB - Irritable bowel syndrome (IBS) is a common, chronic disorder producing disturbances in defecation, abdominal pain, and bloating. While IBS is not considered a life-threatening disease, patients afflicted with it experience a decrease in quality of life. IBS is associated with significant disability, high health care costs, and decreased productivity at work. There is no single pathophysiologic marker for IBS. Application of diagnostic criteria and limited laboratory and clinical testing usually allow for a conclusive diagnosis. Understanding the pathophysiology and psychosocial factors in IBS can better prepare health care providers to improve patient outcomes. Treatment is based on an effective physician-patient relationship in conjunction with pharmacotherapy and behavioral modifications. The advent of new pharmacologic therapies acting at the 5-hyroxytryptamine receptor pathways will enable prescribers to better control IBS symptoms and improve quality of life.

UR - http://www.scopus.com/inward/record.url?scp=0034039407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034039407&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:0034039407

VL - 12

SP - 11

EP - 16

JO - Drug Benefit Trends

JF - Drug Benefit Trends

SN - 1080-5826

IS - SUPPL. B

ER -